Aster Capital Management DIFC Ltd Invests $1.22 Million in Boston Scientific Corporation $BSX

Aster Capital Management DIFC Ltd acquired a new position in Boston Scientific Corporation (NYSE:BSX) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 12,760 shares of the medical equipment provider’s stock, valued at approximately $1,217,000.

Other large investors have also recently made changes to their positions in the company. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific in the 4th quarter worth approximately $26,000. Colonial Trust Co SC grew its position in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares during the last quarter. Bangor Savings Bank grew its position in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in shares of Boston Scientific in the 4th quarter worth approximately $29,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Down 0.5%

Shares of NYSE:BSX opened at $46.69 on Tuesday. The stock has a fifty day simple moving average of $56.05 and a two-hundred day simple moving average of $74.40. The stock has a market capitalization of $69.39 billion, a price-to-earnings ratio of 19.53, a PEG ratio of 0.89 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $45.99 and a 12-month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

BSX has been the topic of a number of recent analyst reports. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Raymond James Financial reiterated an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Mizuho lowered their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. UBS Group lowered their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Finally, Citigroup lowered their target price on Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.